Femasys gains on FDA clearance to market its infertility treatment

Femasys

25/09/2023 22:48

** Biomedical company Femasys'  FEMY.O  shares rise ~97% to
65 cents aftermarket
    ** Company says it has received 510(k) clearance from U.S.
FDA to market FemaSeed, its infertility treatment
    ** Company's shares down ~63% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))